
morphosis

morphosis aejee 1992 mein sthaapit ack biopharmaceutical company haye. company kaa mukhyalaya munich, germany key paas haye aur isaki ack poorna swaamitva vaali sahayak company haye, morphosis us ink., sanyukt raajya america mein boston maa mein. company key paas vibhinn antibody, protein aur peptide praudyogikiyan hain jinka upayog vaha swaamitva aur bhagidar dawa ummidvaaron donon kii khoj aur vikas key liye karati haye. company key paas 100 seey adhik davaaen hain jinaki vibhinn beemariyon key liye jaanch kii jaa rahee haye. jabaki inmein seey kaee koo dawa aur biotech companiyon key saath saajhedaari mein vikasit kiya jaa rhaa haye, morphosis mein cancer aur autoimmune rogon parr dhyaan kendrit karane key saath ack swaamitva pipeline bhee haye. 
morphosis aejee frankfurt stock exchange aur us nasdack stock exchange mein soochibaddh haye.
itihas.
company kii sthaapana 1992 mein hui thee. 1999 mein, morphosis koo ticker prateek "morr" key tahat frankfurt stock exchange mein soochibaddh kiya gayaa thaa.
2004 mein, morphosis aur novartis ney biopharmaceuticals key anusandhaan aur vikas key liye ack ranneetik saajhedaari mein pravesh kiya, jiska 2007 mein vistaar kiya gayaa thaa. atirikt khoj saajhedaari mein shamil theh bayer (1999), roche (2000), santocor (abb jansen biotech, 2000), shering egg (2001) aur fizer (2003).
2008 mein, company kii pahali swaamitva antibody morr 103 (abb otimib) ney naidaanik vikas mein pravesh kiya. rheumatoid gathiya mein ashajanak parinamon key prakaashan key baad, morphosis ney autilimab key liye glaxosmithcline key saath ack licenses samjhaute parr hastakshar kiye. 2019 mein, glaxosmithcline ney otimibab (abb jee. aiss. key. 3196165) key saath ack charan 3 naidaanik vikas karyakram shuru kiya.
2010 mein, morphosis ney zenkor ink key saath ack licenses samjhaute parr hastakshar kiye. morr208 (abb tafsitmab) key liye.
julaai 2017 mein, morphosis kii platform davaaon mein seey pahali koo hamein vipanan manjuri millie. guselkumb (brand naam tremphya), jise johnson aind johnson kii sahayak company genson biotech dwara vikasit aur vyaavsaayikaran kiya jaa rhaa haye, koo pahali baar sanyukt raajya america, europeeya sangh aur kanada mein madhyam seey gambhir pattika psoriasis key upchaar key liye manjuri dee gaee thee.
aprail 2018 mein, ack americi praarambhik saarvajanik peshkash key baad, jisamen company ney $239 million jutaaye, morphosis key americi depository sheyaron ney nasdack stock exchange parr vyaapaar karna shuru curr diyaa, joe "morr" key prateek key tahat bhee thaa."
2018 mein, company ney ack poorna swaamitva vaali us sahayak company, morphosis us ink kii sthaapana kii..
disambar 2019 mein, sakaratmak naidaanik pareekshan parinamon key aadhar parr, company ney punah praapt/apavartak failate badey bee-cell lymphoma key upchaar key liye lenalydomide key sanyojan mein tafacitamab key liye fda koo ack javic licenses aavedan (bla) prastut kiya. prastutikaran koo farwari 2020 mein dakhil karane key liye sweekaar curr liya gayaa thaa, aur dakhil karane parr nirnay agast 2020 mein honey kii ummeed haye.
janwari 2020 mein, morphosis aur insite nigam ney tafsitamab key vaishvik vikas aur vyaavsaayikaran key liye ack sahyog aur licenses samjhaute parr hastakshar kiye. 3 march, 2020 koo samjhaute koo avishvaas manjuri millie aur iss prakaar yeh prabhaavi hoe gayaa.
march 2020 mein, morphosis ney ghoshana kii kii fda ney dakhil karane key liye javic licenses aavedan (bla) koo sweekaar curr liya haye aur tafsitamab key liye prathamikta sameeksha pradaan kii haye, 30 agast, 2020 kii ack prescription dawa upayogkarta shulk adhiniyam (pee. dee. yuu. aff. aeye.) lakshya tithi nirdhaarit kii haye.
31 julaai, 2020 koo, monjuvi (tafsitmab-cxix) koo yuu dwara anumodit kiya gayaa thaa.aiss. aff. dee. aeye. koo lenalydomide key saath sanyojan mein vayask rogiyon key chikitsa upchaar key liye punarpraapt yaa apavartak failate badey bee-cell lymphoma (dee. ell. bee. see. ell.) key saath sanyojan mein anyatha nirdisht naheen kiya gayaa haye, jisamen nimn shreni key lymphoma seey utpann honey vaale dee. ell. bee. see. ell. shamil hain, aur joe autologous stame cell pratyaropan (aeye. aiss. tii.) key liye paatr naheen hain.
pipeline.
disambar 2020 taka, morphosis mein 116 dawa ummidwar they jinhen morphosis aur anya dawa companiyon dwara vikasit kiya gayaa thaa, jinamen seey 28 naidaanik vikas mein they. morphosis dwara vikasit dou antibody pahale seey hii anumodit aur vipanan kiye jaa chuke hain. 
tafasitamab (morr208) ack maanveekrit monoclonal antibody haye joe bee-cell durbhavnaon key upchaar key liye naidaanik vikas mein cd19 key khilaf nirdeshit haye. tafsitamab kaa mulyankan kaee naidaanik parikshanon mein kiya jaa rhaa haye, akele aur anya cancer-rodhi davaaon key sanyojan mein.
felzartamab (morr202) ack maanveekrit monoclonal antibody haye joe anty-plaa2aar-positive membranus nephropathy key upchaar key liye cd38 key khilaf nirdeshit haye, joe gurde koo prabhaavit karane vaali ack autoimmune bimari haye. 2017 mein, morphosis ney grater chean mein felzartamab (jise aaee-maab dwara teeje202 kahaa jaataa haye) koo vikasit karane aur vyaavsaayikaran karane key liye aaee-laib biopharma key saath ack kshetriya licenses samjhauta kiya. felzartamab (morr202/teeje202) vartamaan mein aaee-laib dwara teen naidaanik parikshanon mein jaanch key adheen haye.
ottimb (morr103/jee. aiss. key. 3196165) jee. aim.-see. aiss. aff. key khilaf nirdeshit ack poori tarah seey maanav monoclonal antibody haye. karyakram koo glaxosmithcline key liye licenses praapt haye. vartamaan mein julaai 2019 mein shuru hue sandhishoth mein otilimab key charan 3 key pareekshan kii jaanch kii jaa rahee haye.>
2 march, 2023 koo, morphosis ney ghoshana kii kii company apane preclinical anusandhaan karyakramon koo samaapt curr degi aur sabhi sambandhit gatividhiyon koo bund curr degi. press vigyapti key anusaar, yeh kadam dawa bajar mein chunautiyon dwara uchit haye, joe company koo apani laagat sanrachana koo anukoolit karane aur vikas key madhya seey antim charan mein oncology utpaadon parr sabhi sansadhanon koo adhik dhyaan kendrit karane key liye majboor curr rahey hain.
praudyogiki.
morphosis ney kaee antibody takneekon kii khoj kii haye joe dawa key vikas key liye upayog kii jaati hain.
morphosis kii mukhya takneek hucal (maanav sanyojan antibody library) haye, joe ack phase display baink aur unake anukoolan key liye ack pranali key roop mein duss arab seey adhik poori tarah seey maanav antibody kaa sangrah haye.
haal hii mein vikasit ack anya takneek okp dwi-vishisht antibody takneek haye. morphosis kii okp takneek ack nayaa swaamitva vaalaa "2 + 1" dwi-vishisht antibody praarup haye jisamen aise anuon key vikas aur badey paimaane parr utpaadan koo saral banaane key liye hysicochemical guna hain.

